Last reviewed · How we verify

Felodipine sustained-release tablet

Lee's Pharmaceutical Limited · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Felodipine sustained-release tablet is a Small molecule drug developed by Lee's Pharmaceutical Limited. It is currently FDA-approved.

Felodipine sustained-release tablet is used to treat hypertension and is classified as a mineralocorticoid receptor antagonist. It belongs to the class of small molecule antagonists.

At a glance

Generic nameFelodipine sustained-release tablet
SponsorLee's Pharmaceutical Limited
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Felodipine sustained-release tablet

What is Felodipine sustained-release tablet?

Felodipine sustained-release tablet is a Small molecule drug developed by Lee's Pharmaceutical Limited.

Who makes Felodipine sustained-release tablet?

Felodipine sustained-release tablet is developed and marketed by Lee's Pharmaceutical Limited (see full Lee's Pharmaceutical Limited pipeline at /company/lee-s-pharmaceutical-limited).

What development phase is Felodipine sustained-release tablet in?

Felodipine sustained-release tablet is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing